Evidence map›Paper›PMID 40361424›Full record

ReviewCancers2025

Dana M Hartl, Davide Lombardi, Ricard Simo, Radu Mihai, Aleix Rovira, Enyi Ofo, Iain J Nixon

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Validation for use in Colombia of the EORTC QLQ-THY34 questionnaire to measure quality of life in patients with thyroid cancer.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dana M HartlDivision of Surgery and Anesthesiology, Head and Neck Oncology Service, Thyroid Surgery Unit, Gustave Roussy Cancer Campus Grand Paris, 94800 Villejuif, France.ORCID 0000-0003-1161-5628
Davide LombardiDepartment of Otorhinolaryngology-Head Neck Surgery, University of Brescia, 25121 Brescia, Italy.ORCID 0000-0001-8430-4789
Ricard SimoDepartment of Otorhinolaryngology Head and Neck Surgery, Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London SE1 7EH, UK.ORCID 0000-0002-5410-1566
Radu MihaiDepartment of Endocrine Surgery, Churchill Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Aleix RoviraDepartment of Otorhinolaryngology Head and Neck Surgery, Head, Neck and Thyroid Oncology Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London SE1 7EH, UK.ORCID 0000-0001-8736-4963
Enyi OfoConsultant Otorhinolaryngologist Head and Neck Surgeon, Department of Otorhinolaryngology Head and Neck Surgery, St George's Hospital, London SW17 0QT, UK.
Iain J NixonDepartment of Otolaryngology Head and Neck Surgery, University of Edinburgh, Edinburgh EH8 9YL, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTherapeutic lateral neck dissection is recommended for papillary thyroid cancer with metastatic lymph nodes detected on palpation or on preoperative imaging. Current guidelines recommend systematic dissection of levels IIA, III, IV and VB in these patients. Despite this recommendation, management of level V remains controversial due to a varying degree of clinical and occult lymph node involvement reported in published retrospective studies, but also due to the functional risk involved in level V dissection in which the spinal accessory nerve may be temporarily or permanently injured. The aim of this review was to address the issues involved in level VB dissection and to provide our view of surgical management of level VB.

methodNarrrative review.

resultWe propose a new concept of a partial or "

Indexed as

lateral neck dissectionlevel Vneuromonitoringspinal accessory nervethyroid cancer

Identifiers

PMID40361424
PMCPMC12070824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.